Bivalirudin may be an effective alternative anticoagulant to heparin for use in percutaneous peripheral interventions. We aimed to compare the safety and efficacy of bivalirudin versus heparin as the procedural anticoagulant agent in patients undergoing percutaneous peripheral intervention.
Methods
For this meta-analysis and systematic review, we conducted a search in PubMed, Medline, Embase, and Cochrane for all the clinical studies in which bivalirudin was compared to heparin as the procedural anticoagulant in percutaneous peripheral interventions. Outcomes studied included all-cause mortality, all-bleeding, major and minor bleeding, and access site complications.
Results
Eleven studies were included in the analysis, totaling 20,137 patients. There was a significant difference favoring bivalirudin over heparin for all-cause mortality (risk ratio 0.58, 95% CI 0.39–0.87), all-bleeding (risk ratio 0.62, 95% CI 0.50–0.78), major bleeding (risk ratio 0.61, 95% CI 0.39–0.96), minor bleeding (risk ratio 0.66, 95% CI 0.47–0.92), and access site complications (risk ratio 0.66, 95% CI 0.51–0.84). There was no significant difference in peri-procedural need for blood transfusions (risk ratio 0.79, 95% CI 0.57–1.08), myocardial infarction (risk ratio 0.87, 95% CI 0.59–1.28), stroke (risk ratio 0.77, 95% CI 0.59–1.01), intracranial bleeding (risk ratio 0.77, 95% CI 0.29–2.02), or amputations (OR 0.75, 95% CI 0.53–1.05).
Conclusion
Our meta-analysis suggests that bivalirudin use for percutaneous peripheral interventions is associated with lower all-cause mortality, bleeding, and access site complications as compared to heparin. Further large randomized trials are needed to confirm the current results.
FowkesFGRudanDRudanIet al.
Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet2013;
382: 1329–1340.
2.
MalyarNMFreisingerEMeyborgMet al.
Low rates of revascularization and high in-hospital mortality in patients with ischemic lower limb amputation: morbidity and mortality of ischemic amputation. Angiology2016;
67: 860–869.
3.
AboyansVRiccoJBBartelinkMELet al.
ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J2017;
2017: ▪.
4.
Gerhard-HermanMDGornikHLBarrettCet al.
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol2017;
69: 1465–1508.
5.
ShishehborMHJaffMR.Percutaneous therapies for peripheral artery disease. Circulation2016;
134: 2008–2027.
6.
EfeovbokhanNKhouzamRNAl-FakhouriAet al.
An objective comparison between bivalirudin and heparin during peripheral vascular interventions. Future Cardiol2014;
10: 717–724.
7.
NikolskyEStoneGW.Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin. Future Cardiol2007;
3: 345–364.
8.
StoneGWWitzenbichlerBGuagliumiGet al.
Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med2008;
358: 2218–2230.
9.
AbuRahmaAFMousaAY.Current status of carotid stenting versus endarterectomy. Adv Surg2016;
50: 235–256.
10.
VenkatachalamSShishehborMHGrayBH.Basic data related to endovascular management of peripheral arterial disease in critical limb ischemia. Ann Vasc Surg2012;
26: 1039–1051.
11.
StamlerSKatzenBTTsoukasAIet al.
Clinical experience with the use of bivalirudin in a large population undergoing endovascular abdominal aortic aneurysm repair. J Vasc Interv Radiol2009;
20: 17–21.
12.
LiberatiAAltmanDGTetzlaffJet al.
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med2009;
151: 94. W65-
13.
HigginsJPAltmanDGGotzschePCet al.
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;
343: d5928
14.
WellsGSBO’ConnellDPetersonJet al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. ▪ 2013; ▪.
15.
The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.3 Copenhagen: The Nordic Cochrane Centre, 2014.
16.
SterneJASuttonAJIoannidisJPet al.
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ2011;
343: d4002.
17.
DerSimonianRKackerR.Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials2007;
28: 105–114.
18.
AllieDELirtzmanMDWyattCHet al.
Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions. J Invasive Cardiol2003;
15: 334–342.
19.
GeisbuschPKatzenBTPenaCet al.
Bivalirudin used as alternative anticoagulant in carotid artery stenting: a single center observational study. J Interv Cardiol2012;
25: 197–202.
20.
HallakOShamsSABroceMet al.
Similar success rates with bivalirudin and unfractionated heparin in bare-metal stent implantation. Cardiovasc Intervent Radiol2007;
30: 906–911.
21.
KimmelstielCPintoDAronowHDet al.
Bivalirudin is associated with improved in-hospital outcomes compared with heparin in percutaneous vascular interventions: observational, propensity-matched analysis from the premier hospital database. Circ Cardiovasc Interv2016;
9: e002823
22.
LinPHBushRLPedenEKet al.
Carotid artery stenting with neuroprotection: assessing the learning curve and treatment outcome. Am J Surg2005;
190: 850–857.
23.
OrtizDSinghMJahangirAet al.
Bivalirudin versus unfractionated heparin during peripheral vascular interventions: a propensity-matched study. Cathet Cardiovasc Intervent2017;
89: 408–413.
24.
ShammasNWShammasGAJerinMet al.
In-hospital safety and effectiveness of bivalirudin in percutaneous peripheral interventions: data from a real-world registry. J Endovasc Ther2010;
17: 31–36.
25.
SheikhIRAhmedSHMoriNet al.
Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in percutaneous peripheral intervention: a single-center experience. JACC Cardiovasc Interv2009;
2: 871–876.
26.
StabileESorropagoGTesorioTet al.
Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: results from a prospective randomized study. J Vasc Surg2010;
52: 1505–1510.
27.
WayangankarSAAbu-FadelMSAronowHDet al.
Hemorrhagic and ischemic outcomes after bivalirudin versus unfractionated heparin during carotid artery stenting. Circ Cardiovasc Interv2013;
6: 131–138.
28.
FeitFVoeltzMDAttubatoMJet al.
Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol2007;
100: 1364
29.
WarkentinTESheppardJAHorsewoodPet al.
Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood2000;
96: 1703–1708.
30.
NikolskyESadeghiHMEffronMBet al.
Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol2005;
96: 474–481.
31.
MerliniPARossiMMenozziAet al.
Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation2004;
109: 2203–2206.
32.
KernisSJHarjaiKJStoneGWet al.
The incidence, predictors, and outcomes of early reinfarction after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol2003;
42: 1173
33.
De LucaGErnstNvan 't HofAWet al.
Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J2006;
151: 1256–1259.
34.
MirabetMGarcia-DoradoDRuiz-MeanaMet al.
Thrombin increases cardiomyocyte acute cell death after ischemia and reperfusion. J Mol Cell Cardiol2005;
39: 277–283.
35.
JormalainenMVentoAELukkarinenHet al.
Inhibition of thrombin during reperfusion improves immediate postischemic myocardial function and modulates apoptosis in a porcine model of cardiopulmonary bypass. J Cardiothorac Vasc Anesth2007;
21: 224–231.
36.
OrtizDJahangirASinghMet al.
Access site complications after peripheral vascular interventions: incidence, predictors, and outcomes. Circ Cardiovasc Interv2014;
7: 821–828.
37.
HanYGuoJZhengYet al.
Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA2015;
313: 1336–1346.
38.
StegPGvan ‘t HofAHammCWet al.
Bivalirudin started during emergency transport for primary PCI. N Engl J Med2013;
369: 2207–2217.
39.
StoneGWWhiteHDOhmanEMet al.
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet2007;
369: 907–919.
40.
MehranRLanskyAJWitzenbichlerBet al.
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet2009;
374: 1149–1159.
41.
PiccoloRDe BiaseCD'AnnaCet al.
Early stent thrombosis with bivalirudin in patients undergoing percutaneous coronary intervention. A meta-analysis of randomised clinical trials. Thromb Haemost2015;
113: 1010–1020.
42.
KastratiANeumannFJSchulzSet al.
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med2011;
365: 1980–1989.
43.
GibsonCMMorrowDAMurphySAet al.
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol2006;
47: 2364–2373.
44.
LincoffAMKleimanNSKereiakesDJet al.
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA2004;
292: 696–703.
45.
BriguoriCViscontiGFocaccioAet al.
Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. JACC Cardiovasc Interv2015;
8: 414–423.
46.
KastratiANeumannFJMehilliJet al.
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med2008;
359: 688–696.
47.
PattiGPasceriVD'AntonioLet al.
Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study). Am J Cardiol2012;
110: 478–484.
48.
TavanoDViscontiGD'AndreaDet al.
Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention. Am J Cardiol2009;
104: 1222–1228.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
